



Human Lung Cellular Toxicity Panel

Price: \$4,000 (per lead asset)

Contact: Dr. Erik M. Schwiebert, Ph.D.

2016

Human Lung Cellular Toxicity Panel


Will have:


Four companion plates (see example of a single plate at right) seeded with early passage primary large airway epithelial cells, primary small airway epithelial cells, primary airway smooth muscle cells and primary lung microvascular endothelial cells.


Testing of a single compound, biologic, biosimilar, generic, phytochemical, botanical extract, etc. will therefore be assessed in three different cell types that represent the human lung.

This 2D cell culture assessment will require @10 days from receipt of the hit-to-lead or lead asset to assay report.

If 3D-like studies with cells grown on filter supports or 3D Biogel-grown cultures are also required, please request this in our Custom Program Inquiry page and DBM will provide a quote and more in-depth information and assay sheets.

Media only 

Primary human lung cells 



One plate per compound: 8-point CRC with untreated, vehicle-treated and industry standard positive controls (if applicable) in the middle 60 wells in 2D culture with collagen-coated or uncoated substrates

The price is based on \$1,000 per cell type tested in the panel per lead pharmaceutical asset. If more than 5 lead assets require testing, please use the Custom Inquiry page in the Online Store to request a custom bundled quote. If 3D-like permeable filter support-based culture or 3D Biogel-based culture are required for testing cellular toxicity for your lead asset, please use the Custom Inquiry page in the Online Store to request a customized quote.

The primary human cells used in these studies are provided by a commercial vendor partner, Lifeline Cell Technology, and are used in these assays are early passage (passage 2, 3 or 4).

The cells and the media used are well tested for contaminants.

Thank you for your interest in DBM's Online Store offerings – our belief is that the use of physiologically-relevant human cells from human tissue is most pertinent to pharmaceutical discovery and development – DBM does not compromise on that principle.